Watch Out, Rising Capex Could Turn Today's Cash Cows Into Dogs

Pacer US Cash Cows 100 ETF (COWZ) is up 17% over the past year and has returned 63% over five years, but rising capex in Energy and Pharma is pressuring the free-cash-flow screen that drives the portfolio. ConocoPhillips’ capex rose from $5.3B in 2021 to $12.1B in 2024, cutting implied free cash flow to about $8B from $18.2B in 2022, while Pfizer paid $9.77B in dividends against $9.08B of free cash flow in 2025, implying a 108% payout ratio. The next quarterly rebalance could rotate out of familiar holdings as cash generation weakens across cyclical sectors.

Analysis

The key second-order issue is that COWZ is not really a permanent-quality basket; it is a capital-allocation momentum screen. When management teams defend production, launch capacity, or protect market share by raising capex, they can destroy their own eligibility for the ETF even if the underlying business is still healthy. That creates a self-reinforcing rotation away from sectors where growth is becoming more capex-intensive and toward sectors with structurally lighter reinvestment needs, which should help software, payments, and select consumer staples relative to energy and pharma over the next 1-3 rebalance cycles.

For COP and similar E&Ps, the real risk is not near-term earnings but the mechanical interaction between elevated capex and index ownership. If the market starts to doubt free-cash-flow durability, passive holders can become forced sellers at the exact moment buybacks are still absorbing cash, worsening the bid/ask mismatch and compressing multiples faster than fundamentals alone would imply. That argues for underperformance of capex-heavy cash-return stories versus peers with lower reinvestment intensity, even if oil prices remain range-bound.

PFE is more interesting as a timing setup than a structural short. The market already discounts some policy pressure and pipeline execution risk, but if payout ratios remain above free cash flow for another 2-3 quarters, the dividend narrative becomes harder to defend and could trigger a gradual de-rating rather than an abrupt selloff. The consensus mistake is assuming dividend support makes the stock defensive; in this regime, a stretched payout is a lagging indicator of capital allocation stress, not a margin of safety.

Key Decisions for Investors

• Reduce exposure to COWZ into the next quarterly rebalance; use any strength over the next 2-6 weeks to trim, because the portfolio is likely to keep migrating away from today’s headline names as capex trends remain elevated.
• Initiate a pair trade: long XLU/XLV quality sub-sectors with low reinvestment intensity versus short XLE or COP over 1-3 months; target relative underperformance if capex remains sticky and cash yield screens keep rotating.
• Short COP on a 3-6 month horizon with a stop if upstream capex normalizes or oil rallies materially; the setup is a multiple compression trade tied to FCF yield deterioration, not a bearish crude call.
• Consider a small PFE put spread 2-4 months out to express the risk of dividend credibility erosion; best payoff if payout coverage stays sub-1x through the next earnings cycle.
• If you want exposure to the factor, prefer SCHD over COWZ for a 12-month holding period; lower fees and dividend durability should outperform if cash-yield momentum continues to decay.